Imgt아이엠지티
456570 · KONEX · ₩456570 · 아이엠지티
- Market cap
- ₩57B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−61.4% from the high
₩8,690Today: ₩10,300 – ₩10,970₩28,000
Returns
- 1W−9.9%
- 1M−18.7%
- 3M−13.3%
- 6M−26.1%
- YTD−48.2%
- 1Y−6.0%
- Volume today
- 266
- 0.3× the 20-day average
- Traded today
- ₩2.8M
- Listed shares
- 5,264,804
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+5.1% on Oct 27, 2026.
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Quiet- BuzzQuietBuzz 28 of 100 (50 is a normal day for this stock).
- MomentumWeak-21.6% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Imgt stock overview
Imgt (아이엠지티, KRX: 456570) is listed on KONEX, in the Biotech & Pharma sector. The company researches, develops, and commercializes focused ultrasound medical devices that enhance the intratumoral delivery efficiency of anticancer drugs. Its shares closed at ₩10,800 on Oct 27, 2026, up 5.06% on the day, giving it a market value of ₩57B.
Key facts
- Market cap
- ₩57B
- Sector
- Biotech & Pharma
- Latest price change
- +5.06%
- As of
- Oct 27, 2026
- Main business
- The company researches, develops, and commercializes focused ultrasound medical devices that enhance the intratumoral delivery efficiency of anticancer drugs.
Quick answers about Imgt
- What does Imgt do?
- The company researches, develops, and commercializes focused ultrasound medical devices that enhance the intratumoral delivery efficiency of anticancer drugs. Its core product, the IMD10 system, is used in ChemoSono Therapy, which combines chemotherapy with focused ultrasound, with pancreatic cancer as its first target indication. The company has completed clinical trials at Seoul National University Hospital and is preparing a multinational pivotal trial in the United States and South Korea.
- What is the market cap of Imgt?
- The market capitalisation of Imgt was ₩57B at the close on Oct 27, 2026.
- Who are the largest shareholders of Imgt?
- According to the latest official filings, the largest reported holders are Lee Hak-jong (33.02%, as of May 13, 2025); K2 Investment Partners (13.76%, as of Apr 29, 2025); Korea Investment Partners (5.07%, as of Dec 5, 2024).
- When is the next earnings report from Imgt?
- Korean companies rarely announce results dates in advance. Based on when Imgt filed the same report in past years, its next annual results is expected between Mar 20, 2027 and Apr 7, 2027.
Company profile
The company researches, develops, and commercializes focused ultrasound medical devices that enhance the intratumoral delivery efficiency of anticancer drugs. Its core product, the IMD10 system, is used in ChemoSono Therapy, which combines chemotherapy with focused ultrasound, with pancreatic cancer as its first target indication. The company has completed clinical trials at Seoul National University Hospital and is preparing a multinational pivotal trial in the United States and South Korea.
Written by AI from the company's latest annual report.
- Korean name
- 아이엠지티
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 이학종, 손건호 (각자 대표이사)
- Founded
- Apr 2010
- Listed
- Jul 2023
- Listed shares
- 5,264,804
- Fiscal year ends
- Month 12
- Website
- www.imgt.co.kr/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent filings
See all- Investor relations (IR) eventOct 7, 2026
- Investor relations (IR) eventSep 17, 2026
- [Amended] Notice of Stock Purchase Option GrantSep 4, 2026
- [Amended] Notice of Stock Purchase Option GrantSep 4, 2026
- Notice on Grant of Stock Purchase OptionsSep 4, 2026
Titles in Korean until English translations are added.
Also known as: Imgt / 아이엠지티 / 456570 / KRX:456570
Source: KRX statistical information